Get the Stockscreener App
102.71
28.63%
22.86
After Hours:
89.72
-12.99
-12.65%
Revolution Medicines Inc stock is traded at $102.71, with a volume of 14.47M.
It is up +28.63% in the last 24 hours and up +28.97% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$79.85
Open:
$80.95
24h Volume:
14.47M
Relative Volume:
6.02
Market Cap:
$19.86B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-28.06
EPS:
-3.66
Net Cash Flow:
$-551.11M
1W Performance:
+28.95%
1M Performance:
+28.97%
6M Performance:
+180.09%
1Y Performance:
+131.69%
1-Day Range:
$79.94
$105.00
1-Week Range:
$76.28
$105.00
52-Week Range:
$29.17
$105.00
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
102.71 | 15.44B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
AbbVie (ABBV) Denies Acquisition Talks with Revolution Medicines - GuruFocus
AbbVie (ABBV) Denies Discussions with Revolution Medicines - GuruFocus
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
AbbVie denies media reports of talks to buy Revolution Medicines - Reuters
Pharma Boom: RVMD’s Path to Success - StocksToTrade
AbbVie Says It’s Not in Talks to Buy Revolution Medicines - Bloomberg.com
Revolution Medicines (RVMD) Surges on AbbVie Acquisition Talks - GuruFocus
AbbVie (ABBV) Nears Acquisition Deal with Revolution Medicines - GuruFocus
Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines - TipRanks
AbbVie M&A Buzz Sends Revolution Medicines RVMD Above $100, ABBV Stock $230+ - FXLeaders
Revolution Medicines (RVMD) Stock Surges on Acquisition Talks wi - GuruFocus
AbbVie (ABBV) Nears Acquisition of Cancer-Drug Firm Revolution M - GuruFocus
AbbVie (ABBV) Reportedly Nears Acquisition of Revolution Medicines - GuruFocus
Exclusive | AbbVie Near Deal for Revolution MedicinesWSJ - The Wall Street Journal
AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition - MarketScreener
Revolution Medicines stock surges over 20% on potential AbbVie acquisition By Investing.com - Investing.com Canada
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports - TradingView — Track All Markets
AbbVie Close to Deal for Cancer Drugmaker RevMed, WSJ Says - Bloomberg.com
AbbVie, Revolution Medicines said to be close to deal - breakingthenews.net
Revolution Medicines (NASDAQ:RVMD) Sets New 52-Week HighHere's What Happened - MarketBeat
Revolution Medicines stock hits all-time high at 82.0 USD By Investing.com - Investing.com India
Revolution Medicines stock hits all-time high at 82.0 USD - Investing.com
Revolution Medicines Stock Soars On Report Of AbbVie Takeover - Stocktwits
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib - MSN
Why Revolution Medicines Inc. stock could benefit from AI revolution2026 world cup usa national team quarterfinals goalkeepers low block defense expert forecast analysis - ulpravda.ru
Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
The Technical Signals Behind (RVMD) That Institutions Follow - Stock Traders Daily
Revolution Medicines Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Free Popular Stock Picks Selection - earlytimes.in
Harbor Capital Advisors Inc. Has $1.01 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
What sentiment indicators say about Revolution Medicines Inc. stockLong-Term Investment Plans & Access Free Risk Analysis Before You Invest - Bollywood Helpline
Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Extending Long-Term Upside Potential - TipRanks
Revolution Medicines stock hits all-time high at 81.49 USD By Investing.com - Investing.com Australia
Understanding Momentum Shifts in (RVMD) - news.stocktradersdaily.com
Revolution Medicines (NASDAQ:RVMD) Hits New 52-Week HighHere's What Happened - MarketBeat
Revolution Medicines stock hits all-time high at 81.49 USD - Investing.com
How resilient is Revolution Medicines Inc. stock in market downturns2025 Price Targets & Long-Term Growth Stock Strategies - ulpravda.ru
Trend Review: Will Revolution Medicines Inc. stock deliver long term returnsMarket Risk Report & Scalable Portfolio Growth Methods - ulpravda.ru
Why ETFs are accumulating Revolution Medicines Inc. (42Z) stockQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - DonanımHaber
How Revolution Medicines Inc. stock valuations compare to rivalsWeekly Profit Recap & Capital Protection Trading Alerts - DonanımHaber
Is Revolution Medicines Inc. stock positioned for digital transformationJuly 2025 Earnings & Detailed Earnings Play Alerts - DonanımHaber
Is Revolution Medicines Inc. stock positioned well for digital economyMarket Performance Report & Stepwise Trade Execution Plans - DonanımHaber
Can Revolution Medicines Inc. stock weather global recession - DonanımHaber
Why Revolution Medicines Inc. Equity Warrant stock could outperform in 2025Earnings Growth Report & Low Risk High Reward Ideas - Улправда
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 15,394 Shares of Stock - MarketBeat
Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 3,104 Shares - MarketBeat
Revolution Medicines Insider Sold Shares Worth $1,182,526, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines (RVMD) General Counsel reports Form 4 stock sale - Stock Titan
Revolution Medicines (RVMD) CEO Goldsmith discloses 15,394-share tax-related sale - Stock Titan
[Form 4] Revolution Medicines, Inc. Insider Trading Activity - Stock Titan
Revolution Medicines (RVMD) COO reports 4,847-share sale under Rule 10b5-1 plan - Stock Titan
Revolution Medicines (RVMD) CFO reports 3,104-share sale under 10b5-1 plan - Stock Titan
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):